Axsome Therapeutics Plans New Drug Application for AXS-12 in January, Shares Surge 16.1%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Source: Benzinga
- New Drug Application Plan: Axsome Therapeutics announced its intention to file a new drug application for AXS-12 in January after receiving FDA feedback, which is expected to enhance the company's market share in the mental health sector.
- Priority Review Approval: The FDA granted Priority Review for AXS-05 for Alzheimer's agitation, which will expedite the product's market entry and could lead to significant revenue growth for the company.
- Significant Stock Surge: Axsome Therapeutics' shares rose 16.1% to $172.90 on Wednesday, reflecting strong market confidence in its drug development prospects, potentially attracting more investor interest.
- Positive Market Reaction: Amid a broader market decline, Axsome's stock increased, indicating investor optimism in the biotech sector, which may pave the way for future financing and partnership opportunities for the company.
Analyst Views on AXSM
Wall Street analysts forecast AXSM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXSM is 175.25 USD with a low forecast of 148.00 USD and a high forecast of 202.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
15 Buy
0 Hold
0 Sell
Strong Buy
Current: 177.010
Low
148.00
Averages
175.25
High
202.00
Current: 177.010
Low
148.00
Averages
175.25
High
202.00
About AXSM
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
